Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

Clinical trial NCT06627751 · RECRUITING

Trial details

NCT number: NCT06627751
Sponsor: Roswell Park Cancer Institute
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Extramedullary Disease in Multiple Myeloma Recurrent Multiple Myeloma Refractory Multiple Myeloma

Start date: 2025-05-01
Primary completion: 2027-05-01
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.